Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 11, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13045-018-0675-4
Keywords
FMS-like tyrosine kinase 3 inhibitors; Acute myeloid leukemia; Midostaurin; FLT3
Categories
Ask authors/readers for more resources
FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101. New generation FLT3 inhibitors and combination therapies may overcome resistance to first-generation agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available